Enablers of continuous processing of biotherapeutic products

Anurag S. Rathore; Andrew L. Zydney; Anupa Anupa; Saxena Nikita; Neelesh Gangwar

doi:10.1016/j.tibtech.2021.12.003

Enablers of continuous processing of biotherapeutic products

Anurag S. Rathore, Andrew L. Zydney, Anupa Anupa, Saxena Nikita, Neelesh Gangwar

Research output: Contribution to journal › Review article › peer-review

18 Scopus citations

Abstract

The benefits of continuous processing over batch manufacturing are widely acknowledged across the biopharmaceutical industry, primary of which are higher productivity and greater consistency in product quality. Furthermore, the reduced equipment and facility footprint lead to significantly lower capital costs. Technology enablers have a major role in this migration from batch to continuous processing. In this review, we highlight the various enablers that are facilitating adoption of continuous upstream and downstream bioprocessing. This includes new bioreactors and cell retention devices for upstream operations, and on-column and continuous flow refolding, novel continuous chromatography, and single-pass filtration systems for downstream processes. We also elucidate the significant roles of process integration and control as well as of data analytics in these processes.

Original language	English (US)
Pages (from-to)	804-815
Number of pages	12
Journal	Trends in Biotechnology
Volume	40
Issue number	7
DOIs	https://doi.org/10.1016/j.tibtech.2021.12.003
State	Published - Jul 2022

All Science Journal Classification (ASJC) codes

Biotechnology
Bioengineering

Access to Document

10.1016/j.tibtech.2021.12.003

Cite this

@article{128e51ff39e748eeb30ad249ace98767,

title = "Enablers of continuous processing of biotherapeutic products",

abstract = "The benefits of continuous processing over batch manufacturing are widely acknowledged across the biopharmaceutical industry, primary of which are higher productivity and greater consistency in product quality. Furthermore, the reduced equipment and facility footprint lead to significantly lower capital costs. Technology enablers have a major role in this migration from batch to continuous processing. In this review, we highlight the various enablers that are facilitating adoption of continuous upstream and downstream bioprocessing. This includes new bioreactors and cell retention devices for upstream operations, and on-column and continuous flow refolding, novel continuous chromatography, and single-pass filtration systems for downstream processes. We also elucidate the significant roles of process integration and control as well as of data analytics in these processes.",

author = "Rathore, {Anurag S.} and Zydney, {Andrew L.} and Anupa Anupa and Saxena Nikita and Neelesh Gangwar",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier Ltd",

year = "2022",

month = jul,

doi = "10.1016/j.tibtech.2021.12.003",

language = "English (US)",

volume = "40",

pages = "804--815",

journal = "Trends in Biotechnology",

issn = "0167-7799",

publisher = "Elsevier Ltd",

number = "7",

}

TY - JOUR

T1 - Enablers of continuous processing of biotherapeutic products

AU - Rathore, Anurag S.

AU - Zydney, Andrew L.

AU - Anupa, Anupa

AU - Nikita, Saxena

AU - Gangwar, Neelesh

PY - 2022/7

Y1 - 2022/7

N2 - The benefits of continuous processing over batch manufacturing are widely acknowledged across the biopharmaceutical industry, primary of which are higher productivity and greater consistency in product quality. Furthermore, the reduced equipment and facility footprint lead to significantly lower capital costs. Technology enablers have a major role in this migration from batch to continuous processing. In this review, we highlight the various enablers that are facilitating adoption of continuous upstream and downstream bioprocessing. This includes new bioreactors and cell retention devices for upstream operations, and on-column and continuous flow refolding, novel continuous chromatography, and single-pass filtration systems for downstream processes. We also elucidate the significant roles of process integration and control as well as of data analytics in these processes.

AB - The benefits of continuous processing over batch manufacturing are widely acknowledged across the biopharmaceutical industry, primary of which are higher productivity and greater consistency in product quality. Furthermore, the reduced equipment and facility footprint lead to significantly lower capital costs. Technology enablers have a major role in this migration from batch to continuous processing. In this review, we highlight the various enablers that are facilitating adoption of continuous upstream and downstream bioprocessing. This includes new bioreactors and cell retention devices for upstream operations, and on-column and continuous flow refolding, novel continuous chromatography, and single-pass filtration systems for downstream processes. We also elucidate the significant roles of process integration and control as well as of data analytics in these processes.

UR - http://www.scopus.com/inward/record.url?scp=85122947174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85122947174&partnerID=8YFLogxK

U2 - 10.1016/j.tibtech.2021.12.003

DO - 10.1016/j.tibtech.2021.12.003

M3 - Review article

C2 - 35034769

AN - SCOPUS:85122947174

SN - 0167-7799

VL - 40

SP - 804

EP - 815

JO - Trends in Biotechnology

JF - Trends in Biotechnology

IS - 7

ER -

Enablers of continuous processing of biotherapeutic products

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this